It was recently shown that mTOR inhibitors impair homologous recombination repair and synergize with PARP inhibitors through a negative regulation of SUV39H1 in BRCA-proficient triple-negative breast cancer cell lines [31]. This evidence concerns the gene SUV39H1 and triple-negative breast carcinoma.